메뉴 건너뛰기




Volumn 4, Issue 1, 2013, Pages 53-61

Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus

Author keywords

Asian; Exenatide; Type 2 diabetes

Indexed keywords

AMYLASE; ANTIEMETIC AGENT; C REACTIVE PROTEIN; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

EID: 84873152483     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2012.00238.x     Document Type: Article
Times cited : (72)

References (37)
  • 1
    • 2342466734 scopus 로고    scopus 로고
    • Global prevalence of diabetes: estimates for the year 2000 and projections for 2030
    • Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
    • (2004) Diabetes Care , vol.27 , pp. 1047-1053
    • Wild, S.1    Roglic, G.2    Green, A.3
  • 2
    • 80051986265 scopus 로고    scopus 로고
    • Globalization of Diabetes: the role of diet, lifestyle, and genes
    • Hu FB. Globalization of Diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011; 34: 1249-1257.
    • (2011) Diabetes Care , vol.34 , pp. 1249-1257
    • Hu, F.B.1
  • 3
    • 66149131064 scopus 로고    scopus 로고
    • Diabetes in Asia: epidemiology, risk factors, and pathophysiology
    • Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
    • (2009) JAMA , vol.301 , pp. 2129-2140
    • Chan, J.C.1    Malik, V.2    Jia, W.3
  • 4
    • 0035990614 scopus 로고    scopus 로고
    • Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship
    • Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev 2002; 3: 141-146.
    • (2002) Obes Rev , vol.3 , pp. 141-146
    • Deurenberg, P.1    Deurenberg-Yap, M.2    Guricci, S.3
  • 5
    • 0042879891 scopus 로고    scopus 로고
    • Age, body mass index and Type 2 diabetes-associations modified by ethnicity
    • Nakagami T, Qiao Q, Carstensen B, et al. Age, body mass index and Type 2 diabetes-associations modified by ethnicity. Diabetologia 2003; 46: 1063-1070.
    • (2003) Diabetologia , vol.46 , pp. 1063-1070
    • Nakagami, T.1    Qiao, Q.2    Carstensen, B.3
  • 6
    • 1942423595 scopus 로고    scopus 로고
    • The associations of body mass index, C-peptide and metabolic status in Chinese Type 2 diabetic patients
    • Chan WB, Tong PC, Chow CC, et al. The associations of body mass index, C-peptide and metabolic status in Chinese Type 2 diabetic patients. Diabet Med 2004; 21: 349-353.
    • (2004) Diabet Med , vol.21 , pp. 349-353
    • Chan, W.B.1    Tong, P.C.2    Chow, C.C.3
  • 7
    • 3042672692 scopus 로고    scopus 로고
    • Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes
    • Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004; 53: 831-835.
    • (2004) Metabolism , vol.53 , pp. 831-835
    • Fukushima, M.1    Usami, M.2    Ikeda, M.3
  • 8
    • 0037212264 scopus 로고    scopus 로고
    • Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance
    • Kuroe A, Fukushima M, Usami M, et al. Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance. Diabetes Res Clin Pract 2003; 59: 71-77.
    • (2003) Diabetes Res Clin Pract , vol.59 , pp. 71-77
    • Kuroe, A.1    Fukushima, M.2    Usami, M.3
  • 9
    • 57349160286 scopus 로고    scopus 로고
    • Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
    • (2009) Diabetologia , vol.52 , pp. 17-30
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 10
    • 29944436303 scopus 로고    scopus 로고
    • International Diabetes Federation. International Diabetes Federation, Available at (accessed 6 July 2011).
    • International Diabetes Federation. Global Guideline for Type 2 Diabetes. International Diabetes Federation, 2005. Available at http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf (accessed 6 July 2011).
    • (2005) Global Guideline for Type 2 Diabetes
  • 11
    • 33745250519 scopus 로고    scopus 로고
    • The status of diabetes control and antidiabetic drug therapy in Japan-a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1)
    • Kobayashi M, Yamazaki K, Hirao K, et al. The status of diabetes control and antidiabetic drug therapy in Japan-a cross-sectional survey of 17, 000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 2006; 73: 198-204.
    • (2006) Diabetes Res Clin Pract , vol.73 , pp. 198-204
    • Kobayashi, M.1    Yamazaki, K.2    Hirao, K.3
  • 12
    • 77954731903 scopus 로고    scopus 로고
    • Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients
    • Arai K, Matoba K, Hirao K, et al. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15, 652 patients. Endocr J 2010; 57: 499-507.
    • (2010) Endocr J , vol.57 , pp. 499-507
    • Arai, K.1    Matoba, K.2    Hirao, K.3
  • 13
    • 0032511566 scopus 로고    scopus 로고
    • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
    • UK Prospective Diabetes Study (UKPDS) Group.
    • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
    • (1998) Lancet , vol.352 , pp. 854-865
  • 14
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 15
    • 0031964322 scopus 로고    scopus 로고
    • UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
    • UK Prospective Diabetes Study Group.
    • UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87-92.
    • (1998) Diabetes Care , vol.21 , pp. 87-92
  • 16
    • 84873199812 scopus 로고    scopus 로고
    • (exenatide) [abbreviated prescribing information]. Eli Lilly and Company Limited, Basingstoke, Available at (accessed 3 August 2011).
    • Bydureon (exenatide) [abbreviated prescribing information]. Eli Lilly and Company Limited, Basingstoke, 2011. Available at http://www.bydureonlaunch.co.uk/templates/lilly/bydureon/ downloads/prescribing-information.pdf (accessed 3 August 2011).
    • (2011) Bydureon
  • 17
    • 15444367142 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
    • Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181.
    • (2005) Am J Health Syst Pharm , vol.62 , pp. 173-181
    • Kolterman, O.G.1    Kim, D.D.2    Shen, L.3
  • 18
    • 0347360186 scopus 로고    scopus 로고
    • Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
    • Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77-88.
    • (2004) Regul Pept , vol.117 , pp. 77-88
    • Nielsen, L.L.1    Young, A.A.2    Parkes, D.G.3
  • 19
    • 57949096314 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea
    • Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009; 83: 69-76.
    • (2009) Diabetes Res Clin Pract , vol.83 , pp. 69-76
    • Gao, Y.1    Yoon, K.H.2    Chuang, L.M.3
  • 20
    • 79961065111 scopus 로고    scopus 로고
    • Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks
    • Kadowaki T, Namba M, Imaoka T, et al. Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Invest 2011; 2: 210-217.
    • (2011) J Diabetes Invest , vol.2 , pp. 210-217
    • Kadowaki, T.1    Namba, M.2    Imaoka, T.3
  • 21
    • 67650490677 scopus 로고    scopus 로고
    • Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes
    • Kadowaki T, Namba M, Yamamura A, et al. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009; 56: 415-424.
    • (2009) Endocr J , vol.56 , pp. 415-424
    • Kadowaki, T.1    Namba, M.2    Yamamura, A.3
  • 22
    • 17144371646 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    • Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
    • (2005) Diabetes Care , vol.28 , pp. 1083-1091
    • Kendall, D.M.1    Riddle, M.C.2    Rosenstock, J.3
  • 23
    • 0037045845 scopus 로고    scopus 로고
    • Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study
    • Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
    • (2002) Lancet , vol.359 , pp. 824-830
    • Zander, M.1    Madsbad, S.2    Madsen, J.L.3
  • 24
    • 34247259577 scopus 로고    scopus 로고
    • The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial
    • Zinman B, Hoogwerf BJ, Duran GarciaS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-485.
    • (2007) Ann Intern Med , vol.146 , pp. 477-485
    • Zinman, B.1    Hoogwerf, B.J.2    Duran, G.3
  • 25
    • 18144401971 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    • DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
    • (2005) Diabetes Care , vol.28 , pp. 1092-1100
    • DeFronzo, R.A.1    Ratner, R.E.2    Han, J.3
  • 26
    • 34249891874 scopus 로고    scopus 로고
    • Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
    • Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487-1493.
    • (2007) Diabetes Care , vol.30 , pp. 1487-1493
    • Kim, D.1    MacConell, L.2    Zhuang, D.3
  • 27
    • 79955960213 scopus 로고    scopus 로고
    • DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
    • Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011; 28: 705-714.
    • (2011) Diabet Med , vol.28 , pp. 705-714
    • Wysham, C.1    Bergenstal, R.2    Malloy, J.3
  • 28
    • 73549096393 scopus 로고    scopus 로고
    • Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes
    • Iwamoto K, Nasu R, Yamamura A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J 2009; 56: 951-962.
    • (2009) Endocr J , vol.56 , pp. 951-962
    • Iwamoto, K.1    Nasu, R.2    Yamamura, A.3
  • 29
    • 53249142132 scopus 로고    scopus 로고
    • Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
    • Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
    • (2008) Lancet , vol.372 , pp. 1240-1250
    • Drucker, D.J.1    Buse, J.B.2    Taylor, K.3
  • 30
    • 56549107405 scopus 로고    scopus 로고
    • Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
    • Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008; 151: 123-129.
    • (2008) Regul Pept , vol.151 , pp. 123-129
    • Linnebjerg, H.1    Park, S.2    Kothare, P.A.3
  • 31
    • 79955661908 scopus 로고    scopus 로고
    • DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
    • Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-1310.
    • (2011) J Clin Endocrinol Metab , vol.96 , pp. 1301-1310
    • Blevins, T.1    Pullman, J.2    Malloy, J.3
  • 32
    • 77953859640 scopus 로고    scopus 로고
    • Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
    • Diamant M, Van GaalL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-2243.
    • (2010) Lancet , vol.375 , pp. 2234-2243
    • Diamant, M.1    Van, G.2    Stranks, S.3
  • 33
    • 14744287394 scopus 로고    scopus 로고
    • Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations
    • Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005; 34: 77-98.
    • (2005) Endocrinol Metab Clin North Am , vol.34 , pp. 77-98
    • Riddle, M.C.1
  • 34
    • 7444228521 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
    • Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
    • (2004) Diabetes Care , vol.27 , pp. 2628-2635
    • Buse, J.B.1    Henry, R.R.2    Han, J.3
  • 35
    • 4644300651 scopus 로고    scopus 로고
    • Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes
    • Fineman MS, Shen LZ, Taylor K, et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004; 20: 411-417.
    • (2004) Diabetes Metab Res Rev , vol.20 , pp. 411-417
    • Fineman, M.S.1    Shen, L.Z.2    Taylor, K.3
  • 36
    • 0343247711 scopus 로고    scopus 로고
    • Biodegradation and biocompatibility of PLA and PLGA microspheres
    • Anderson J, Shive M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28: 5-24.
    • (1997) Adv Drug Deliv Rev , vol.28 , pp. 5-24
    • Anderson, J.1    Shive, M.2
  • 37
    • 84860250733 scopus 로고    scopus 로고
    • Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment
    • Fineman MS, Mace MF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012; 14: 546-554.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 546-554
    • Fineman, M.S.1    Mace, M.F.2    Diamant, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.